ASLAN Pharmaceuticals Initial Public Offering and NASDAQ Listing

Davis Polk advised the joint book-running managers and representatives of the underwriters in the approximately $42.2 million initial public offering by ASLAN Pharmaceuticals Limited of 6,000,000 American Depositary Shares. The ADSs are listed on the NASDAQ Global Select Market under the symbol “ASLN.”

ASLAN Pharmaceuticals is a clinical-stage, oncology-focused biopharmaceutical company developing novel therapeutics for global markets. ASLAN targets diseases that are both highly prevalent in Asia and orphan indications in the United States and Europe. 

The Davis Polk corporate team included partner Alan F. Denenberg and associates Donald K. Lang, Randy Li and Katherine Schloss Ackerman. Counsel Michelle Ontiveros Gross and associate Jason J. Bang provided intellectual property and technology advice. Counsel Marcie A. Goldstein provided FINRA advice. Members of the Davis Polk team are based in the Northern California and New York offices.